• 1
    European Liver Transplant Registry. Data Analysis Booklet. Paris: 2007: .
  • 2
    Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int 2008; 12: 1107.
  • 3
    Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ. Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am 2009; 2: 325.
  • 4
    Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007; 3: 391.
  • 5
    Mazzaferro V, Llovet JM, Miceli R, et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 1: 35.
  • 6
    Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 5: 633.
  • 7
    Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162.
  • 8
    Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 3: 451.
  • 9
    Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 7: 982.
  • 10
    Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced CRC: a randomized GERCOR study. J Clin Oncol 2004; 2: 229.
  • 11
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic CRC. N Engl J Med 2004; 23: 2335.
  • 12
    Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 14: 1408.
  • 13
    Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 10: 1626.
  • 14
    McCarter MD, Fong Y. Metastatic liver tumors. Semin Surg Oncol 2000; 2: 177.
  • 15
    Mentha G, Majno P, Terraz S, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol 2007; 33(Suppl 2): S76.
  • 16
    Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials 2009; 1: 56.
  • 17
    National Institutes of Health Consensus Development Conference Statement: liver transplantation -- June 20–23, 1983. Hepatology 1984; 4 (1 Suppl): 107S.
  • 18
    Aune S, Schistad G, Skulberg A. Human liver transplantation without azathioprine. Surg Gynecol Obstet 1972; 5: 727.
  • 19
    Pichlmayr R, Neuhaus P. Liver transplantation. Chirurg 1985; 4: 211.
  • 20
    Pichlmayr R. Is there a place for liver grafting for malignancy? Transplant Proc 1988; 1(Suppl 1): 478.
  • 21
    Mühlbacher F, Piza F. Orthotopic liver transplantation for secondary malignancies of the liver. Transplant Proc 1987; 19: 2396.
  • 22
    Mühlbacher F, Huk I, Steininger R, et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc 1991; 23: 1567.
  • 23
    Kappel S, Kandioler D, Steininger R, et al. Genetic detection of lymph node micrometastases: a selection criterion for liver transplantation in patients with liver metastases after colorectal cancer. Transplantation 2006; 1: 64.
  • 24
    Nordic Liver Transplant Registy.
  • 25
    Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: recipient characteristics and outcome. Clin Transpl 1995; 19.
  • 26
    Robinson P. Hepatocellular carcinoma: development and early detection. Cancer Imaging 2008; 8(Suppl A): S128.
  • 27
    Kattan MW, Gönen M, Jarnagin WR, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247: 282.
  • 28
    Pawlik TM, Choti MA. Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Oncol Rep 2007; 3: 193.
  • 29
    Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007; 5: 62.
  • 30
    Sandel MH, Dadabayev AR, Menon AG, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005; 7: 2576.
  • 31
    Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960.
  • 32
    Abdel-Misih SR, Schmidt CR, Bloomston PM. Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol 2009; 7: 72.
  • 33
    Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818.
  • 34
    Nordlinger B, Van Cutsem E, Gruenberger T, et al. European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 6: 985.
  • 35
    Neeff H, Hörth W, Makowiec F, et al. Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg 2009; 13: 1813.
  • 36
    Carpizo DR, D’Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol 2009; 16: 2411.
  • 37
    Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. Eur J Cardiothorac Surg 2009; 35: 444.
  • 38
    Yamakado K, Inoue Y, Takao M, et al. Long-term results of radiofrequency ablation in colorectal lung metastases: single center experience. Oncol Rep 2009; 22: 885.
  • 39
    De Jong MC, Mayo SC, Pulitano C, et al. Repeat Curative Intent Liver Surgery is Safe and Effective for Recurrent Colorectal Liver Metastasis: Results from an International Multi-institutional Analysis. J Gastrointest Surg 2009; 13: 2141.
  • 40
    Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644.
  • 41
    Adam R, Wicherts D, De Haas RJ, et al. Patients with initially unresectable colorectal Liver Metastases: Is There a Possibility of Cure? J Clin Oncol 2009; 27: 1829.
  • 42
    De Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250: 440.
  • 43
    Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 2005; 11: 267.
  • 44
    Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23: 5314.
  • 45
    Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909.
  • 46
    Yadav RV, Indudhara R, Kumar P, Chugh KS, Gupta KL. Cyclophosphamide in renal transplantation. Transplantation 1988; 45: 421.
  • 47
    Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 2008; 27: 5886.
  • 48
    Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080.
  • 49
    Dueland S, Andersen M, Foss A. Quality of life (QoL) in colorectal cancer liver transplant patients. J Clin Oncol 2009 (27), ASCO-GI abstract nr. 438.
  • 50
    Van Der Hilst CS, Ijtsma AJ, Slooff MJ, Tenvergert EM. Cost of liver transplantation: a systematic review and meta-analysis comparing the United States with other OECD countries. Med Care Res Rev 2009; 66: 3.
  • 51
    Aaserud M, Kristiansen I S, Neilson A, et al. Helseøkonomisk evaluering av bevacizumab ved metastatisk kolorektalcancer. Rapport fra Kunnskapssenteret nr 23 - 2007. ISBN 978-82-8121-186-5 ISSN 1890-1298. (Summary in english at:
  • 52
    Movik E, Hamidi V, Aaserud M, Neilson AR, Klemp M. Helseøkonomisk evaluering av cetuximab ved metastatisk kolorektalcancer. Rapport Nr 10-2008 Nasjonalt kunnskapssenter. (Summary in english at:
  • 53
    Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg 2002; 26: 257.
  • 54
  • 55
  • 56
  • 57
    Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl 2003; 9: 1019.
  • 58
    McCashland T, Watt K, Lyden E, et al. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007; 13: 1246.
  • 59
    Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Eng Med 2007; 356: 1545.
  • 60
    Yamada T, Tanaka K, Uryuhara K, Ito K, Takada Y, Uemoto S. Selective hemi-portocaval shunt based on portal vein pressure for small-for-size graft in adult living donor liver transplantation. Am J Transplant 2008; 8: 847.